Cellmid Limited Information

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Through its Advangen business, Cellmid sells its FGF5 inhibitor hair growth products in Australia, Japan, the U.S and expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.myevolis.com.au

Website	http://www.cellmid.com.au
Ticker	CDY
Revenue	$5.4 million
Funding	$7 million
Employees	4 (0 on RocketReach)
Founded	2004
Address	55 Clarence St L 2 Ste 204, Sydney, New South Wales 2000, AU
Phone	+61 2 9221 6830
Fax	+61 2 9221 8535
Technologies	JavaScript , HTML , PHP +15 more (view full list)
Industry	Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering, Therapeutics, Health Care
Web Rank	16 Million
Keywords	Life Sciences, Biotechnology, Fibrotic Diseases, Therapeutics, Novel Therapies, Drug Discovery, Diagnostic Tests, Biopharma, Cell Therapy, Drug Development, Pharmaceutical, Clinical Trials, Molecular Diagnostics, Regenerative Medicine, Biomarkers, Health Technology, Medical Technology, Immunology, Research, Healthcare
Competitors	Amgen, GSK, Eisai Co., Ltd., Roche, Genzyme Europe B.V., Bristol Myers Squibb, Pfizer, Receptos, a wholly-owned subsidiary of Celgene, AstraZeneca, Johnson & Johnson +40 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 87 Companies, SIC Code 873 Companies, SIC Code 283 Companies
NAICS	NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 54 Companies